BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Making Significant Strides to Advance Cellular Therapy Programs
Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty. “The company is guided by the mission to advance cell-based product candidates into pivotal phase 3 trials, with the goal of attaining regulatory approvals and subsequently commercializing the product. Longeveron has so far made significant strides in line with this mission,” reads a recent article that discussed attendance by the company’s CEO Wa’el Hashad and EVP and CFO Lisa Locklear at the recent 25th Annual H.C. Wainwright Global Investment Conference. At the…